Crystal structure of the EphA4 protein tyrosine kinase domain in the apo- and dasatinib-bound state

FEBS Letters

Volumn 585, Issue 22, 2011, Pages 3593-3599

  Farenc, Carine ^a   Celie, Patrick H N ^b   Tensen, Cornelis P ^c   De Esch, Iwan J P ^d   Siegal, Gregg ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Dasatinib; EphA4; Receptor tyrosine kinase; Three dimensional structure; X ray crystallography

Indexed keywords

ADENOSINE TRIPHOSPHATE; APOLIPOPROTEIN; DASATINIB; EPHRIN A4; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENTROPY; ENZYME ACTIVATION; HYDROPHOBICITY; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SEQUENCE HOMOLOGY; X RAY CRYSTALLOGRAPHY;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIGANDS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PYRIMIDINES; RECEPTOR, EPHA4; THIAZOLES;

EID: 80855143629     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2011.10.028     Document Type: Article

References (41)

1. P. van der Geer, T. Hunter, and R.A. Lindberg Receptor protein-tyrosine kinases and their signal transduction pathways Annu. Rev. Cell Biol. 10 1994 251 337 (Pubitemid 24372822)
2. N. Cheng, D.M. Brantley, and J. Chen The ephrins and Eph receptors in angiogenesis Cytokine Growth Factor Rev. 13 2002 75 85 (Pubitemid 34436963)
3. E.B. Pasquale Eph-ephrin bidirectional signaling in physiology and disease Cell 133 2008 38 52 (Pubitemid 351442996)
4. (1997). Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee. Cell 90, 403-404.
5. E.B. Pasquale Eph receptor signalling casts a wide net on cell behaviour Nat. Rev. Mol. Cell Biol. 6 2005 462 475 (Pubitemid 40780558)
6. A.D. Bergemann, L. Zhang, M.K. Chiang, R. Brambilla, R. Klein, and J.G. Flanagan Ephrin-B3, a ligand for the receptor EphB3, expressed at the midline of the developing neural tube Oncogene 16 1998 471 480 (Pubitemid 28062074)
7. N.W. Gale Elk-L3, a novel transmembrane ligand for the Eph family of receptor tyrosine kinases, expressed in embryonic floor plate, roof plate and hindbrain segments Oncogene 13 1996 1343 1352 (Pubitemid 26343588)
8. N.W. Gale Eph receptors and Ligands comprise Two major Specificity subclasses and are reciprocally compartmentilized during embryogenesis Neuron 17 1996 9 19 (Pubitemid 26251587)
9. J. Gong Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer Int. J. Oncol. 36 2010 101 106
10. S. Ashida Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs Cancer Res. 64 2004 5963 5972 (Pubitemid 39129392)
11. R. van Doorn, R. Dijkman, M.H. Vermeer, J.J. Out-Luiting, E.M. van der Raaij-Helmer, R. Willemze, and C.P. Tensen Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis Cancer Res. 64 2004 5578 5586 (Pubitemid 39095552)
12. Y. Goldshmit, M.P. Galea, G. Wise, P.F. Bartlett, and A.M. Turnley Axonal regeneration and lack of astrocytic gliosis in EphA4-deficient mice J. Neurosci. 24 2004 10064 10073 (Pubitemid 39492030)
13. K.K. Murai, and E.B. Pasquale 'Eph'ective signaling: forward, reverse and crosstalk J. Cell Sci. 116 2003 2823 2832 (Pubitemid 36926971)
14. K.L. Binns, P.P. Taylor, F. Sicheri, T. Pawson, and S.J. Holland Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors Mol. Cell. Biol. 20 2000 4791 4805 (Pubitemid 30396126)
15. L.E. Wybenga-Groot, B. Baskin, S.H. Ong, J. Tong, T. Pawson, and F. Sicheri Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region Cell 106 2001 745 757 (Pubitemid 32900665)
16. S. Wiesner, L.E. Wybenga-Groot, N. Warner, H. Lin, T. Pawson, J.D. Forman-Kay, and F. Sicheri A change in conformational dynamics underlies the activation of Eph receptor tyrosine kinases EMBO J. 25 2006 4686 4696 (Pubitemid 44498140)
17. N.P. Shah, C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399 401 (Pubitemid 38938156)
18. L.J. Lombardo Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2- hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5- carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J. Med. Chem. 47 2004 6658 6661 (Pubitemid 40053752)
19. J. Li A chemical and phosphoproteomic characterization of dasatinib action in lung cancer Nat. Chem. Biol. 6 2010 291 299
20. M.W. Karaman A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26 2008 127 132
21. T. O'Hare In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res. 65 2005 4500 4505 (Pubitemid 40740783)
22. W. Kabsch Xds Acta Crystallogr. D Biol. Crystallogr. 66 2010 125 132
23. P. Evans Scaling and assessment of data quality Acta Crystallogr. D Biol. Crystallogr. 62 2006 72 82
24. M.J. Winn Overview of the current CCP4 suite and current developments Acta Crystallogr. D. 67 2011 235 242
25. J. Navaza Implementation of molecular replacement in AMoRe Acta Crystallogr. D Biol. Crystallogr. 57 2001 1367 1372 (Pubitemid 36117184)
26. G. Langer, S.X. Cohen, V.S. Lamzin, and A. Perrakis Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7 Nat. Protoc. 3 2008 1171 1179
27. G.N. Murshudov, A.A. Vagin, and E.J. Dodson Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr. D Biol. Crystallogr. 53 1997 240 255 (Pubitemid 27235885)
28. P.D. Adams PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr. D Biol. Crystallogr. 66 2010 213 221
29. P. Emsley, and K. Cowtan Coot: model-building tools for molecular graphics Acta Crystallogr. D Biol. Crystallogr. 60 2004 2126 2132 (Pubitemid 41742764)
30. A.P. Kornev, S.S. Taylor, and L.F. Ten Eyck A helix scaffold for the assembly of active protein kinases Proc. Natl. Acad. Sci. USA 105 2008 14377 14382
31. S.R. Hubbard, M. Mohammadi, and J. Schlessinger Autoregulatory mechanisms in protein-tyrosine kinases J. Biol. Chem. 273 1998 11987 11990 (Pubitemid 28240552)
32. M. Huse, and J. Kuriyan The conformational plasticity of protein kinases Cell 109 2002 275 282 (Pubitemid 34606870)
33. S.W. Cowan-Jacob, H. Mobitz, and D. Fabbro Structural biology contributions to tyrosine kinase drug discovery Curr. Opin. Cell Biol. 21 2009 280 287
34. J. Nowakowski Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography Structure 10 2002 1659 1667 (Pubitemid 35452573)
35. L.E. Kay, D.R. Muhandiram, N.A. Farrow, Y. Aubin, and J.D. Forman-Kay Correlation between dynamics and high affinity binding in an SH2 domain interaction Biochemistry 35 1996 361 368 (Pubitemid 26032693)
36. Y. Liu, K. Shah, F. Yang, L. Witucki, and K.M. Shokat A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src Bioorg. Med. Chem. 6 1998 1219 1226 (Pubitemid 28398957)
37. H. Daub, K. Specht, and A. Ullrich Strategies to overcome resistance to targeted protein kinase inhibitors Nat. Rev. Drug. Discov. 3 2004 1001 1010 (Pubitemid 39642363)
38. M. Getlik, C. Grutter, J.R. Simard, S. Kluter, M. Rabiller, H.B. Rode, A. Robubi, and D. Rauh Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc J. Med. Chem. 52 2009 3915 3926
39. N.K. Williams, I.S. Lucet, S.P. Klinken, E. Ingley, and J. Rossjohn Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state J. Biol. Chem. 284 2009 284 291
40. J.S. Tokarski The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants Cancer Res. 66 2006 5790 5797 (Pubitemid 43927133)
41. D.J. Marcotte Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases Protein Sci. 19 2010 429 439